Abstract:746 Background: Selpercatinib, a first-in-class highly selective and potent RET kinase inhibitor with CNS activity, is approved in multiple countries for the treatment of RET-activated cancers. This update includes more patients (pts, n=52) and 16 months (mo) longer follow-up (data cut-off: 13Jan2023) in RET fusion+ solid tumors other than lung/thyroid with a focus on GI histologies. Methods: The phase 1/2 LIBRETTO-001 trial (NCT03157128) enrolled pts with locally advanced/metastatic RET fusion+ solid tumors. 51/52 pts received the recommended dose of 160 mg orally. The efficacy analysis set consisted of pts enrolled ≥6 months prior to the cut-off date. Primary endpoint was objective response rate (ORR) by independent review committee (IRC). Secondary endpoints included ORR by investigator (INV), duration of response (DoR), progression-free survival (PFS), and safety. Results: Of the 52 pts with RET-activated solid tumors other than lung or thyroid, 51.9% were female with a median age of 54.0 years. The majority (31/52) of patients had GI RET fusion+ tumor types, with pancreatic (N=13) and colorectal (N=13) as the most common (Table). 47 pts received prior systemic therapy (median prior lines: 2, range 0-9); 28.8% received ≥3 lines. In 52 efficacy-evaluable pts, confirmed ORR by IRC was 44.2% (23/52, 95% CI: 30.5, 58.7). ORR by IRC for pts with pancreatic tumors was 53.8% and for colorectal tumors was 30.8%. Clinical benefit (complete response + partial response + stable disease ≥16 weeks) was observed in 67.3% (35/52) of pts. Median DoR was 37.2 mo (95% CI: 13.3, NE) for overall pts (Table). No new safety signals were identified compared to previous reports. 4 grade 5 AEs were observed (unrelated to treatment by INV), and 2 pts discontinued due to treatment-related AEs per INV. Conclusions: Selpercatinib continued to demonstrate durable antitumor activity and tolerable safety in pts with RET fusion+ cancers across multiple tumor types and fusion partners, including difficult-to-treat GI cancers with poor results in standard-of-care options, such as pancreatic and colorectal. These results emphasize the importance of comprehensive genomic profiling across all tumor types in order to identify actionable oncogenic drivers, including RET fusions. Clinical trial information: NCT03157128 .[Table: see text]

Adverse event profiles of selpercatinib: a real-world pharmacovigilance analysis based on FAERS database

Efficacy and Safety of Selpercatinib in Chinese Patients with Advanced RET Fusion-Positive Non-Small-cell Lung Cancer: a Phase II Clinical Trial (LIBRETTO-321).

Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system

Intracranial Activity of Selpercatinib in Chinese Patients with AdvancedRETFusion–Positive Non–Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

Selpercatinib Monotherapy in a Chinese Patient with RET Fusion/ EGFR Co-Mutated Nonsmall Cell Lung Cancer from the Phase II LIBRETTO-321 Study: a Case Report.

Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced <i>RET</i> fusion-positive non-small-cell lung cancer and thyroid cancer, and <i>RET</i>-mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial

Clinical Activity of Selpercatinib in RET -mutant Pheochromocytoma

A case of organizing pneumonia in rearranged during transfection fusion-positive lung adenocarcinoma treated with selpercatinib

Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea

CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non–Small Cell Lung Cancer

Cost-effectiveness analysis of selpercatinib versus chemotherapy and pembrolizumab in the first-line treatment of rearranged during transfection fusion–positive non-small cell lung cancer in the United States

Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC

Durable efficacy of selpercatinib in patients with RET fusion+ solid tumors, with a focus on GI tumors: LIBRETTO-001.

Efficacy and Safety of Selpercatinib in Chinese Patients with Advanced RET-altered Thyroid Cancers: Results from the Phase II LIBRETTO-321 Study

Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer and thyroid cancer, and RET -mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial.

A real-world pharmacovigilance study of KRAS G12C mutation inhibitors based on the food and drug administration adverse event reporting system

Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA Adverse Event Reporting System

Rapid response to selpercatinib in RET fusion positive pancreatic neuroendocrine carcinoma confirmed by smartwatch

Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event Reporting System (FAERS) database: A real-world pharmacovigilance study

Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report